PE20190912A1 - Compuesto de piridona como inhibidor de c-met - Google Patents

Compuesto de piridona como inhibidor de c-met

Info

Publication number
PE20190912A1
PE20190912A1 PE2019000855A PE2019000855A PE20190912A1 PE 20190912 A1 PE20190912 A1 PE 20190912A1 PE 2019000855 A PE2019000855 A PE 2019000855A PE 2019000855 A PE2019000855 A PE 2019000855A PE 20190912 A1 PE20190912 A1 PE 20190912A1
Authority
PE
Peru
Prior art keywords
refers
pharmaceutically acceptable
met inhibitor
pyridone compound
compounds
Prior art date
Application number
PE2019000855A
Other languages
English (en)
Inventor
Xiongbin Xu
Gang Li
Charles Z Ding
Lihong Hu
Guoping Hu
Jian Li
Shuhui Chen
Zhigang Chi
Kun Wang
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of PE20190912A1 publication Critical patent/PE20190912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se refiere a compuestos derivados de piridona de Formula (I), o una sal farmaceuticamente aceptable; donde R1 puede ser H o F; R2 puede ser H o CH3; A puede ser fenilo, piridilo, pirazolilo, isoxazolilo, entre otros; cada uno de los cuales esta opcionalmente sustituido con 1, 2 o 3 R3; R3 puede ser CN, halogeno, entre otros. Tambien se refiere a una composicion farmaceutica que comprende una cantidad terapeuticamente eficaz, asi como un vehiculo farmaceuticamente aceptable. Dichos compuestos van a modular la actividad de la proteina c-Met codificada por el protooncogen Met que es un receptor tirosina quinasa con alta union que pertenece al subgrupo RON y son utiles en el tratamiento del cancer.
PE2019000855A 2016-10-27 2017-10-27 Compuesto de piridona como inhibidor de c-met PE20190912A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (1)

Publication Number Publication Date
PE20190912A1 true PE20190912A1 (es) 2019-06-26

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000855A PE20190912A1 (es) 2016-10-27 2017-10-27 Compuesto de piridona como inhibidor de c-met

Country Status (28)

Country Link
US (1) US10501443B2 (es)
EP (1) EP3533787B1 (es)
JP (1) JP6719679B2 (es)
KR (1) KR102070748B1 (es)
CN (1) CN109311812B (es)
AU (1) AU2017348810B2 (es)
BR (1) BR112019008415B1 (es)
CA (1) CA3041164C (es)
CO (1) CO2019005165A2 (es)
DK (1) DK3533787T3 (es)
EA (1) EA038108B1 (es)
ES (1) ES2835301T3 (es)
HR (1) HRP20201985T1 (es)
HU (1) HUE051734T2 (es)
IL (1) IL266126B (es)
LT (1) LT3533787T (es)
MX (1) MX2019004626A (es)
MY (1) MY189557A (es)
PE (1) PE20190912A1 (es)
PH (1) PH12019500875A1 (es)
PL (1) PL3533787T3 (es)
PT (1) PT3533787T (es)
RS (1) RS61126B1 (es)
SG (1) SG11201903801YA (es)
SI (1) SI3533787T1 (es)
UA (1) UA122737C2 (es)
WO (1) WO2018077227A1 (es)
ZA (1) ZA201903074B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI768205B (zh) * 2018-04-26 2022-06-21 大陸商福建廣生堂藥業股份有限公司 一種c-MET抑制劑的晶型及其鹽型和製備方法
KR102660608B1 (ko) 2019-02-01 2024-04-26 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. c-Met억제제로서 피리미디닐기를 포함하는 삼환식 화합물
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413241A1 (en) * 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
AU2005219784B2 (en) 2004-03-05 2010-09-02 Msd K.K. Pyridone derivative
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
WO2013057101A1 (de) * 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
MX2014010982A (es) * 2012-03-19 2014-10-13 Merck Patent Gmbh Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancerosa con otros compuestos antitumorales.
CN104703655A (zh) * 2012-10-11 2015-06-10 默克专利股份公司 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合
KR20170090498A (ko) * 2014-12-11 2017-08-07 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합

Also Published As

Publication number Publication date
HUE051734T2 (hu) 2021-03-29
JP2019535806A (ja) 2019-12-12
BR112019008415A2 (pt) 2019-07-09
AU2017348810A1 (en) 2019-05-23
CN109311812A (zh) 2019-02-05
SI3533787T1 (sl) 2021-01-29
CA3041164C (en) 2019-12-17
KR20190058678A (ko) 2019-05-29
ZA201903074B (en) 2020-01-29
BR112019008415B1 (pt) 2020-09-29
AU2017348810B2 (en) 2020-05-07
CN109311812B (zh) 2020-03-17
EA201990952A1 (ru) 2019-11-29
PT3533787T (pt) 2020-11-20
UA122737C2 (uk) 2020-12-28
NZ753020A (en) 2021-08-27
RS61126B1 (sr) 2020-12-31
CA3041164A1 (en) 2018-05-03
MY189557A (en) 2022-02-16
PL3533787T3 (pl) 2021-03-08
JP6719679B2 (ja) 2020-07-08
PH12019500875A1 (en) 2019-06-17
EP3533787A1 (en) 2019-09-04
EA038108B1 (ru) 2021-07-07
US10501443B2 (en) 2019-12-10
DK3533787T3 (da) 2020-11-30
US20190248763A1 (en) 2019-08-15
EP3533787A4 (en) 2019-11-13
ES2835301T3 (es) 2021-06-22
MX2019004626A (es) 2019-11-08
EP3533787B1 (en) 2020-09-30
HRP20201985T1 (hr) 2021-02-05
SG11201903801YA (en) 2019-05-30
LT3533787T (lt) 2020-11-25
CO2019005165A2 (es) 2019-05-31
KR102070748B1 (ko) 2020-01-29
IL266126B (en) 2020-07-30
IL266126A (en) 2019-06-30
WO2018077227A1 (zh) 2018-05-03

Similar Documents

Publication Publication Date Title
PE20190912A1 (es) Compuesto de piridona como inhibidor de c-met
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
NI201000032A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos.
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
PE20181345A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer